The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Cancer History ProjectGuest Editorial

Paul Calabresi: A founder and giant in the field of medical oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS
Celia and Paul Calabresi at the Matterhorn

The story of modern cancer therapy would not be complete without the inclusion of the work of Paul Calabresi and some insights about the challenges he faced, along with his accomplishments.

For this chapter in the Cancer History Project, I revised and extended a Memorial I wrote for Paul in 2006. I also had the pleasure of interviewing many who knew him well including his children: Steven Calabresi, Janice Calabresi Maggs and Peter A. Calabresi, MD. Others gave generously of their time to speak with me and share stories and experiences which I hope will add some richness to Paul’s contributions as an oncologist.

Read the full story here, with commentary by Wafik El-Deiry
Byline
Fred Schiffman, MD, MACP
Sigal Family Professor of Humanistic Medicine;
Vice Chairman of Medicine, Warren Alpert Medical School of Brown University; Medical Director of the Lifespan Cancer Institute; Associate Physician-in-Chief, The Miriam Hospital
Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.
By Jacquelyn Cobb and Sara Willa Ernst
Byline
Fred Schiffman, MD, MACP
Sigal Family Professor of Humanistic Medicine;
Vice Chairman of Medicine, Warren Alpert Medical School of Brown University; Medical Director of the Lifespan Cancer Institute; Associate Physician-in-Chief, The Miriam Hospital
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account